Parul Doshi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4980890/publications.pdf

Version: 2024-02-01

17	1,225	623188	887659
papers	citations	14 h-index	17 g-index

18	18	18	2164
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Resolving the daratumumab interference with blood compatibility testing. Transfusion, 2015, 55, 1545-1554.	0.8	204
2	Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79. Blood, 2014, 124, 3474-3474.	0.6	150
3	STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open, 2020, 5, e000706.	2.0	139
4	When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion, 2015, 55, 1555-1562.	0.8	131
5	Enhancement of paclitaxel and carboplatin therapies byÂCCL2 blockade in ovarian cancers. Molecular Oncology, 2014, 8, 1231-1239.	2.1	85
6	CNTO 95, a fully human anti Î±v integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clinical and Experimental Metastasis, 2008, 25, 139-148.	1.7	83
7	Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1Î² in tumor-associated macrophages. OncoImmunology, 2017, 6, e1334744.	2.1	81
8	Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 974-982.	0.5	79
9	International validation of a dithiothreitol (DTT)â€based method to resolve the daratumumab interference with blood compatibility testing. Transfusion, 2016, 56, 2964-2972.	0.8	76
10	Two Î±-tubulin genes of Aspergillus nidulans encode divergent proteins. Molecular Genetics and Genomics, 1991, 225, 129-141.	2.4	43
11	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemiaâ€“Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 1493-1505.	3.2	38
12	Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica, 2016, 101, e339-e342.	1.7	34
13	Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 44-51.	0.2	30
14	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica, 2020, 105, 1032-1041.	1.7	29
15	Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Experimental Hematology and Oncology, 2018, 7, 27.	2.0	15
16	Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. International Journal of Molecular Medicine, 2002, 10, 385.	1.8	2
17	International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing. Blood, 2015, 126, 3567-3567.	0.6	2